West Pharmaceutical Services (WST) Q4 2025 earnings summary

Executive summary

• Achieved record FY25 net sales of $3.074 billion, up 6.3% reported and 4.3% organic, with strong growth in biologics, GLP-1, and high-value products (HVP).

• Adjusted EPS grew 8% for the year to $7.29, with Q4 adjusted EPS up 12.1% to $2.04.

• Free cash flow increased 69.6% year-over-year to $468.9 million, driven by higher operating cash flow and reduced capital expenditures.

• Growth fueled by HVP components, especially in biologics, biosimilars, and GLP-1 markets, and supported by regulatory and capacity expansion initiatives.

• Strategic divestiture of SmartDose 3.5 mL business, ramp-up of Dublin drug handling operations, and $134 million in share repurchases.

Financial highlights

• Q4 revenues reached $805 million, up 7.5% reported and 3.3% organically year-over-year.

• FY25 gross margin improved to 35.9% (+140 bps), with Q4 gross margin at 37.8% (+130 bps); adjusted operating margin for the year was 20.2%.

• Full-year operating cash flow was $754.8 million (+15.5%), capex $285.9 million (-24.2%), and free cash flow $468.9 million (+69.6%).

• Ended 2025 with $791 million in cash and a net increase in cash and cash equivalents of $306.7 million.

• Q4 net income was $132.1 million (16% margin); full-year net income was $493.7 million (16% margin).

Outlook and guidance

• 2026 organic revenue growth expected at 5%-7%, with reported revenue of $3.215-$3.275 billion.

• Adjusted EPS guidance for 2026 is $7.85-$8.20, representing 7.7%-12.5% growth.

• Q1 2026 revenue expected at $770-$790 million, with adjusted EPS of $1.65-$1.70, up 13%-16% year-over-year.

• CapEx expected to be $250-$275 million in 2026, 6%-8% of sales.

• HVP components and biologics to drive most growth, with GLP-1s expected to grow ~10% in 2026.